Plasma Proteomics Characteristics of Subclinical Vitamin E Deficiency of Dairy Cows During Early Lactation

Weidong Qian, Hongyi Yu, Cuiyu Zhang, Hongyou Zhang, Shixin Fu* and Cheng Xia*

Heilongjiang Provincial Key Laboratory of Prevention and Control of Bovine Diseases, College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing, China

Vitamin E (VE) is an essential fat-soluble nutrient for dairy cows. Vitamin E deficiency leads to immune suppression and oxidative stress and increases the susceptibility of cows to reproductive disorders in the early post-partum period. However, studies on plasma proteomics of VE deficiency have not been reported so far. Therefore, the purpose of this study was to understand the changes of blood protein profile in cows with subclinical VE deficiency in the early post-partum period. In this study, plasma protein levels of 14 healthy cows (>4 µg/ml α-tocopherol) and 13 subclinical VE-deficient cows (2–3 µg/ml α-tocopherol) were analyzed by tandem mass tag (TMT). The results showed that there were 26 differentially expressed proteins (DEPs) in the plasma of cows with subclinical VE deficiency compared with healthy controls. Twenty-one kinds of proteins were downregulated, and five kinds were upregulated, among which eight proteins in protein–protein interactions (PPI) network had direct interaction. These proteins are mainly involved in the MAPK signaling pathway, pantothenic acid and coenzyme A (CoA) biosynthesis, PPAR signaling pathway, and glycosylphosphatidylinositol (GPI)-anchor biosynthesis. The top four DEPs in PPI (APOC3, APOC4, SAA4, PHLD) and one important protein (VNN1) by literature review were further verified by ELISA and Western blot. The expression levels of APOC3, VNN1, and SAA4 were significantly lower than those of healthy controls by ELISA, VNN1 was significantly lower than those of healthy controls by Western blot. VNN1 is closely related to dairy cow subclinical VE deficiency and can be a potential biomarker. It lays a foundation for further research on the lack of pathological mechanism and antioxidative stress of VE.

Keywords: subclinical VE deficiency, TMT, differentially expressed proteins, biomarkers, plasma

INTRODUCTION

The development of the dairy industry is closely related to the regulation of vitamin nutrition, which is the key problem in dairy cows’ healthy breeding (1). Vitamin E (VE) is one of the most important components of cellular antioxidant systems and involved in maintaining the oxidative stability (2). The main function of VE is to protect lipid peroxidation, scavenge free radicals in vivo, so as to maintain the integrity of cell membrane function (3). Dietary vitamin additives, forage, and legume silage are the main sources of VE for dairy cows (4, 5). A large number of studies on dairy cows show that the plasma VE concentration decreased gradually before and after delivery and reached the minimum value before and after calving (6–8).
Although with the continuous progress of dairy cows’ feeding and management, serious VE deficiency in dairy cows rarely occurs. However, during the transition period, in order to enhance the antioxidant capacity of cow cells, excessive consumption of vitamin E will be caused to achieve the purpose of scavenging the oxidative free radicals of excess cells (6, 9). This process makes early post-partum cows prone to subclinical VE deficiency and systemic oxidative stress. Plasma concentrations of α-tocopherol in cows at 2–3 µg/ml can be identified as subclinical VE deficiency (10–12). Vitamin E deficiency and oxidative stress are important causes of perinatal dairy cows’ susceptibility to productive diseases (13). Studies have found that VE deficiency can increase the risk of diseases such as retention of placenta, hysteritis, and mastitis in cows (13, 14). Because there were no practical early monitoring methods to measure the level of VE, subclinical VE deficiency is difficult to be found in due time, which brings serious economic losses to the dairy industry. Therefore, the search for new characteristic biomarkers of subclinical VE deficiency is a key technical problem to be solved in the early monitoring and rapid diagnosis of subclinical VE deficiency for high-yield dairy cows.

Mass spectrometry (MS) has become the preferred method for large-scale protein identification and characterization due to its sensitivity and specificity (15, 16). The MS analysis has been found to reveal changes in protein expression. These proteins can be identified as intermediate biomarkers of early disease effects (17). Tandem mass tag (TMT) is a kind of chemical label used for molecular recognition and quantification based on MS. The TMT has been established as an effective method for proteome quantification (18). The body fluid often detected in the clinic is blood, which is easy to obtain and contains abundant biological information of physiological and pathological processes (19). In this study, proteomics techniques were used to identify the differentially expressed proteins (DEPs) in the plasma between subclinical VE deficiency and healthy cows in the early post-partum period. To the best of our knowledge, no data have been published on plasma proteins in early lactation with subclinical VE deficiency in dairy cows. Thus, this is a comprehensive study to explore the potential biological significance of DEPs between subclinical VE deficiency and healthy cows, providing valuable insights into subclinical VE deficiency plasma proteins that may be applied for developing diagnostic markers in subclinical VE deficiency.

MATERIALS AND METHODS

Animals and Experimental Design

All animals involved in this study were cared for according to the principles of Heilongjiang Bayi Agricultural University Animal Care and Use Committee (Daqing, China). The experiment was conducted at a large intensive cattle farm in Heilongjiang Province (Suihua, China). All Holstein cows were fed the same total mixed ratio diets (in accordance with NRC 2001 standard) with similar age, parity, body condition score, and milk yield. The cows were fed a total mixed ratio diet during early lactation, which mainly consisted of 39.58% of corn, 19.61% of corn silage, 26.99% of Leymus chinensis, 8.48% of soybean meal, and 4.21% of concentrated feed at the early stage of lactation (ingredient, % of DM). The basal diet was formulated to meet the nutrient requirements according to the Feeding Standards of Dairy Cattle in China. Detailed feed composition is shown in Supplementary Table 1.

According to the concentration of α-tocopherol in plasma, the subclinical VE deficiency group (2–3 µg/ml α-tocopherol) and the healthy control group (>4 µg/ml α-tocopherol) were determined (10–12). Finally, after excluding all other cases of perinatal disease, 67 cows were selected as test animals. Thirteen cows were used as the subclinical VE deficiency group (QF), and 14 cows were used as the healthy control group (BQF) for proteomics study. In addition, 40 cows were used for ELISA verification of the screened and identified differential proteins.

Blood Sample Collection

For this study, blood samples were obtained from the coccygeal veins of 80 transition dairy cows from 0 to 30 days after calving. The blood samples of each cow were collected on an empty stomach in the morning. Plasma was obtained by centrifugation of blood collected in a 10 ml lithium-heparin tube. After centrifugation at 4°C for 10 min (3,000 rpm), the supernatant was collected for secondary centrifugation by high speed (12,000 rpm) for 5 min. The supernatant was placed in a 1.5 ml centrifuge tube and cryopreserved at −80°C until analyzed. All samples used for repetitive analysis were frozen in aliquots, and only vials needed for each assay run were used, to avoid the repetitive thawing and freezing effect.

Plasma Sample Processing and TMT Labeling

To determine the biomarkers of subclinical VE deficiency, 27 plasma samples were analyzed by protein quality inspection, trypsin digestion, and TMT differential labeling. Total protein concentration determination was assessed using a Bradford method (20) (Enzyme labeled instrument, Thermo: Multiskan MK3, USA). Firstly, the sample was diluted with lysis buffer to make its final concentration fall within the range of standard curve. The diluted sample and standard sample (bovine serum albumin, BSA: Sigma-Aldrich, A2058, AUS; BSA was dissolved into a series of standard protein by lysis buffer) were diluted with 5 and 250 µl protein quantitative dye, respectively, and the light absorption value of standard substance and sample at 595 nm was determined by enzyme label instrument. The standard curve was drawn, and the sample concentration was calculated. Then, the protein concentration of each sample was calculated according to the curve formula, and the protein concentration of each sample could meet the requirements of the next experiment.

After protein quantification, 100 µg of protein per sample solution was put into a centrifuge tube, and the final volume was 100 µl with Dissolution Buffer (Thermo Scientific, PN: 1861436). Then, 25 µl of 100 mM reducing reagent (Thermo Scientific, PN:1861438) was added and incubated at 55°C for 1 h, and 5 µl of 375 mM iodoacetamide solution (Thermo Scientific, PN: 1861445) was added and incubated for 30 min in a dark room. The processed samples were transferred to a 10 kDa ultrafiltration tube (Sartorius, PN: VN01H02), and 200 µl of 100 mM dissolution buffer was added, centrifuged at 12,000 g for 20 min, discarded the solution at the bottom of the collecting
tube, and repeated four times (pH value should be measured at 8.0). Trypsin (Thermo Scientific, PN: 1862748) was added to the sample (2.5 µl/per sample, 37°C for 14 h). On the next day, the samples were washed with ultrapure water three times, and the bottom of the enrichment tube was lyophilized and then redissolved with 100 mM dissolution buffer.

TandemMassTag™ (TMT™) technology is an in vitro peptide labeling technology developed by Thermo Scientific. In this experiment, 27 serum samples were divided into three groups by labeling with 10 isotopes. The amino groups of peptides were specifically labeled and then analyzed by tandem MS. The relative protein content of 10 different samples in each group could be compared simultaneously. After thawing at room temperature, the TMT reagent (10 standard TMT Kit, Thermo Scientific, PN: 90111) was opened, and 0.8 mg of TMT reagent and 41 µl of absolute ethanol were added into each tube and vibrated for 5 min. Then, 100 µl of enzyme digested sample was added (100 µl/sample) and reacted for 1 h at room temperature. Next, 8 µl of 5% of quenching reagent (Thermo Scientific, PN: 1861439) was added and incubated for 15 min to terminate the reaction. After the labeled samples were mixed, vortex oscillation was performed and centrifuged to the bottom of the tube. The sample after vacuum freeze centrifugation is frozen and stored for use (Vacuum freeze dryer, Thermo: SPD2010-230).

Pre-separation of Enzymatic Peptides and LC–MS/MS Analysis

Rigoll-3000 high performance liquid chromatography system was used to separate the samples at high pH (Beijing Puyuan Jingdian Technology Co., Ltd). The experimental methods in this part refer to the proteomic studies published by Zhao et al. (21). The mixed labeled samples were dissolved in 100 µl mobile phase A (98% ddH2O, 2% acetonitrile, pH 10) and centrifuged at 14,000g for 20 min, and the supernatant was taken for use. Firstly, the system condition was detected, and 400 µl BSA was used for separation (column temperature 45°C, detection wavelength 214 nm). Then, 100 µl of the prepared sample was separated in mobile phase B (98% acetonitrile, 2% ddH2O, pH 10) with a linear gradient of 5–95% over 72 min at the flow rate of 0.7 ml/min, in detail Supplementary Table 2.

Each fraction was injected for nanoLC–MS/MS analysis (high performance liquid chromatography: Thermo Scientific EASY-nLC 1000 System, Nano HPLC; MS system: Thermo, Orbitrap Fusion Lumos). The components obtained by reverse phase separation at high pH were redissolved with 20 µl of 2% methanol and 0.1% formic acid (centrifuged at 12,000 rpm for 10 min), 10 µl of supernatant was aspirated, and the sample was loaded by sandwich method (loading pump flow rate to 350 nl/min for 15 min) and mobile phase B (100% acetonitrile, 0.1% formic acid) with a linear gradient of 6–95% over 75 min at the flow rate of 600 nl/min, in detail Supplementary Table 3.

Protein Identification and Quantification

The obtained data were processed by UniProt_Bovin (2019.07.16 Download) database for MS. Maxquant, the commercial software supporting Thermo Company, was used to process the original MS file to obtain the quantitative value of the sample. The detailed parameters are retrieved in Supplementary Table 4.
**Bioinformatics Analysis of DEPs**
Clustering of Orthologous Groups (COG) analysis is realized by Blast to kyva sequence, and then statistical analysis is carried out to draw the corresponding graph. Gene Ontology (GO) is a standard vocabulary describing the function, location, and activity of genes. It has a tree structure and is the most widely used ontology in molecular biology. KEGG is a Kyoto Encyclopedia of Genes and Genomes (http://www.genome.jp/kegg).

**Enzyme-Linked Immunosorbent Assay**
According to the α-tocopherol concentration in plasma, 40 cows were divided into the subclinical VE deficiency group and healthy control group (the same as the Animals and Experimental Design section). Plasma levels of apolipoprotein C3 (APOC3), apolipoprotein A4 (APOC4), serum amyloid protein A4 (SAA4), phosphatidylinositol-glycan-specific phospholipase D (PHLD), and pantetheinase-1 (VNN1) were determined by enzyme-linked immunosorbent assays according to the manufacturer’s instructions (ELISA kits, Shanghai Sinovac Biotechnology Co., Ltd., China). Optical density was measured at 450 nm using a microplate reader (Thermo Multiskan FC microplate reader).

**Western Blotting Analysis**
Lysates from plasma samples from normal or subclinical VE deficiency were separated on a 10% SDS-PAGE gel, and the proteins were then transferred to a nitrocellulose membrane. The membrane was blocked in TBST containing 5% non-fat milk powder for 1 h and then incubated overnight with primary antibodies against VNN1 protein; the primary antibody used was anti-VNN1 (dilution 1:1,000, rabbit, LSBio, USA, LS-C374585) and washed three times with TBST (5 min each), and then the membrane was incubated for 1 h at room temperature with horseradish peroxidase conjugated rabbit IgG. Antibody binding was detected using enhanced chemiluminescence ECL Plus Western blotting detection reagents (GE).

**TABLE 1 | Proteins showing significant differences in abundance between plasma from cows with subclinical vitamin E deficiency and healthy control.**

| IDa       | Gene name | Protein name | FDR- corrected p-value | Fold_changeb | Changec |
|-----------|-----------|--------------|------------------------|--------------|---------|
| C4T8B4_BOVIN | CRP      | Pentraxin     | 0.000055               | –2.030082929 | ↓       |
| G3X6K8_BOVIN | HP       | Haptoglobin   | 0.000488               | –1.826079462 | ↓       |
| APOC3_BOVIN   | APOC3    | Apolipoprotein C-III | 0.000048        | –1.418673822 | ↓       |
| Q1RMN9_BOVIN   | –        | C4b-binding protein alpha-like | 0.001169       | –0.912143442 | ↓       |
| APOC4_BOVIN   | APOC4    | Apolipoprotein C-IV | 0.0000173          | –0.808904848 | ↓       |
| VNN1_BOVIN   | VNN1     | Pantetheinase  | 0.001734               | –0.743960694 | ↓       |
| F1MJK3_BOVIN   | –        | Uncharacterized protein | 0.000734        | –0.711301256 | ↓       |
| F1N0H3_BOVIN   | CA2      | Carbonic anhydrase 2 | 0.002981        | –0.698077617 | ↓       |
| SAA4_BOVIN   | SAA4     | Serum amyloid A-4 protein | 0.007418       | –0.683821812 | ↓       |
| Q32PA1_BOVIN   | CD59     | CD59 molecule  | 0.000926               | –0.522598997 | ↓       |
| Q2K1W1_BOVIN   | PON1     | Paraoxonase 1  | 0.00612                | –0.476851592 | ↓       |
| F1MRD0_BOVIN   | ACTB     | Actin, cytoplasmic 1  | 0.006124            | –0.463760059 | ↓       |
| LBP_BOVIN    | LBP      | Lipopolysaccharide-binding protein | 0.037565    | –0.45306513   | ↓       |
| PHLD_BOVIN   | GPLD1    | Phosphatidylinositol-glycan-specific phospholipase D | 0.000006     | –0.447579644 | ↓       |
| E1B805_BOVIN | –        | Uncharacterized protein | 0.007075     | –0.422350628 | ↓       |
| A0A3B0I2F8_BOVIN | C1QC   | Adiponectin B  | 0.038116                | –0.403812868 | ↓       |
| A0A3Q1L84_BOVIN | –        | Uncharacterized protein | 0.01683      | –0.400490686 | ↓       |
| A0A3Q1L04_BOVIN | YIPF1   | Protein YIPF   | 0.017006               | –0.387877785 | ↓       |
| A0A3Q1LS74_BOVIN | CFH     | Complement factor H | 0.029566    | –0.3054647518 | ↓       |
| F6PSK5_BOVIN | IL1RAP  | Interleukin 1 receptor accessory protein | 0.003925    | –0.285444103 | ↓       |
| F1MMP5_BOVIN | ITIH1    | Inter-alpha-trypsin inhibitor heavy chain H1 | 0.030626     | –0.27646765 | ↓       |
| FA10_BOVIN | F10      | Coagulation factor X | 0.036694     | 0.280035783   | ↑       |
| HABP2_BOVIN | HABP2    | Hyaluronan-binding protein 2 | 0.002546    | 0.306909645   | ↑       |
| COMP_BOVIN | COMP     | Cartilage oligomeric matrix protein | 0.029325    | 0.350653389   | ↑       |
| REG1_BOVIN | –        | Regaline-1     | 0.01005                | 0.546089842  | ↑       |
| CD14_BOVIN | CD14     | Monocyte differentiation antigen CD14 | 0.000123    | 0.756308843   | ↑       |

aID from NCBI protein database for BOVIN.
bDisplays the protein name of the comment in the Fasta header column.
cFold changes calculated as: –log2 (mean disease/mean control), mean value of peak area obtained from the QF group/mean value of peak area obtained from the BQF group. Choose p-value 0.05 and fold change 1.2 times as significant difference (21).
d“↑”, upregulated plasma proteins; “↓”, downregulated plasma proteins.
Statistical Analysis

The basic information analyses were performed using SPSS statistical software (V18.0), which was considered significant when the \( p \)-value was below 0.05. MS data analyses used the Uniprot_BOVIN (2019.07.16 download) database. The original MS of TMT file is processed by Maxquant, a commercial software of Thermo Company. When the \( p \)-value is 0.05 and fold change 1.2 times, the difference protein is determined to have significant difference (21).

RESULTS

Proteomics of TMT Method to Determine Protein Expression

The experimental workflow of proteomic analysis is shown in Figure 1. The clinical characteristics of the subclinical VE deficiency group (QF) and normal control group (BQF) samples for proteomic analysis are shown in Supplementary Figure 1. According to the Uniprot_BOVIN database, 3,614 peptides (Supplementary Table 5) and 270 proteins (Supplementary Table 6) were identified in the protein qualitative results, which revealed 26 DEPs. The specific information concerning the DEPs is shown in Table 1. Compared with the healthy control group, the DEPs in the plasma of the subclinical VE deficiency group were 21 downregulated proteins and 5 upregulated proteins (Figures 2, 3).

Functional Annotation and Analysis

Clusters of Orthologous Groups analysis was based on the homologous classification of gene products based on the COG database. The analysis identified protein ortholog classifications via the COG database, allowing us to predict the possible functions of these proteins and potentially uncover further functional classifications. The highest protein functional classifications were defense mechanisms with 28 proteins, general function prediction with 20 proteins, post-translational modification, protein turnover, and chaperones with 15 proteins, amino acid transport and metabolism with 10 proteins, and signal transduction mechanisms with 15 proteins (Figure 4).

To understand the cellular and molecular functions (MF) of subclinical VE deficiency-related proteins, GO analysis of these related proteins was performed based on biological processes (BP), cellular components (CC), and MF. In this analysis, the protein number was used to assess the importance of subclinical VE deficiency-related proteins in regulating cellular and molecular functions (Figure 5). Based on BP, these subclinical VE deficiency-related proteins were mainly involved in innate immune response, triglyceride homeostasis, negative regulation of triglyceride, G protein-coupled receptor signaling,
inflammatory response, and phosphatidylcholine metabolic process. The higher enrichment of CC was the plasma membrane and high-density lipoprotein (HDL) particle, and the functions of higher MF enrichment were calcium ion binding and phospholipid binding.

For KEGG signaling pathway analysis, these subclinical VE deficiency-related proteins are mainly involved in the MAPK signaling pathway, and these subclinical VE deficiency downregulated differential-related proteins are mainly involved in pantothenate and CoA biosynthesis, PPAR signaling pathway, and glycosylphosphatidylinositol (GPI)-anchor biosynthesis (Figure 6).

Interaction Network Between Proteins
In this study, 26 differential proteins were obtained through high-throughput screening. Based on the STRING PPI (protein–protein interaction) database and Cytoscape tools, we established a PPI network and found that 10 of these proteins have direct interactions. In the network, the number of proteins that directly interact with a certain protein A is called the connection degree of protein A. Generally speaking, the greater the connection degree of a protein, the greater the disturbance to the entire system when the protein changes; this protein may be the key to maintaining the balance and stability of the system. The Cytoscape was used as a tool to set the size of the node to reflect the degree of the node. A larger node indicates a higher degree of the node. The top four proteins were selected in the degree of the node in this network as candidate proteins for subsequent experimental verification, namely, APOC3, APOC4, SAA4, and PHLD (Figure 7).

Reduced Plasma Levels of VNN1, SAA4, APOC3, APOC4, and PHLD in Cows With Subclinical VE Deficiency
To validate differentially expressed candidate proteins between the subclinical VE deficiency group and the healthy control group, 40 plasma samples were verified (20 subclinical VE deficiency and 20 healthy plasma) by ELISA. The top four DEPs in PPI (APOC3, APOC4, SAA4, PHLD) and one important protein (VNN1) by literature review were further verified by ELISA. The results showed that VNN1, SAA4, and APOC4 were significantly downregulated in subclinical VE deficiency plasma samples ($p < 0.05$; Figure 8), while the expression levels of PHLD and APOC3, protein were not significantly changed ($p > 0.05$).

Confirmation of Differentially Regulated Proteins by Western Blot
Four samples (the subclinical VE deficiency group and the healthy control group) were selected from the collected plasma samples, and Western blot analysis was performed on one healthy control group) were selected from the collected plasma samples, and Western blot analysis was performed on one healthy control group. The results of Western blot provide reliable evidence for TMT proteomics.
Haptoglobin is an acute phase protein released by hepatocytes in response to the production of pro-inflammatory cytokines in an inflammatory state (26). Lipopolysaccharide-binding protein is an acute phase protein synthesized in the liver that is involved in the host response to both Gram-negative and Gram-positive pathogens (27); it also promotes the presentation of lipopolysaccharide LPS to CD14 and induces the release of pro-inflammatory cytokines (28). Serum amyloid A-4 protein is a secondary apolipoprotein on HDL in plasma (29). Studies have shown that the concentration of SAA4 decreases when the body is under inflammation (30, 31). The expression of regakine-1 and F10 was upregulated. It indicates that subclinical VE deficiency may aggravate the inflammatory response of the body and increase the risk of infection with other diseases. The expression of CD59, CRP, HP, LBP, and SAA4 was downregulated in the subclinical deficiency group, suggesting that the subclinical deficiency of VE may impair the innate immune response of the body, leading to inflammation and immunosuppression. However, its molecular mechanism needs to be further studied.

The involvement of hyaluronan-binding protein 2 (HABP2), apolipoprotein C4 (APOC4), paraoxonase 1 (PON1), complement factor H (CFH), inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1), and APOC3 in triglyceride homeostasis and negative triglyceride regulation is significant in DEPs. Hyaluronan-binding protein 2 is a calcium-dependent serine protease that provides structural and functional integrity for cells and plays an important role in blood coagulation and fibrinolysis (32). Apolipoprotein C-IV expression is regulated by the oxisome proliferation-activated receptor complex and is associated with hepatic steatosis (33). PON1 is a mammalian antioxidant/anti-inflammatory enzyme synthesized in the liver and secreted into the blood (34). Complement factor H is a major MDA binding protein that can induce the pro-inflammatory effects of MDA (35). Inter-alpha-trypsin inhibitor heavy chain H1 is one of the heavy chains of serine protease inhibitors that carry hyaluronic acid in plasma and play a role in inflammation and carcinogenesis (36). APOC3 is recognized as one of the most important regulators of plasma triglyceride (37). APOC3 of bovine is a low molecular weight protein mainly synthesized by the liver and mainly distributed in HDL (38, 39).

Under normal conditions, APOC3 concentration in bovine plasma was the lowest in the non-lactation period and gradually increased in the early lactation stage. In the early lactation period, the plasma APOC3 concentration of cows with fatty liver and ketosis was lower than that of healthy cows (40, 41). In the subclinical VE deficiency group, HABP2 was upregulated, while CFH, ITIH1, and APOC3 were downregulated, indicating that subclinical VE deficiency can aggravate lipid peroxidation, cause oxidative stress induced by inflammatory response, and may cause hyaluronic acid synthesis and transport disorders at the cellular level, thus affecting extracellular matrix synthesis and changing cell structural integrity (42). PON1 is involved in the hydrolysis of lipid hydroperoxides and phospholipids.
produced during oxidative stress (43), which may be the main reason for the downregulation of VE in subclinical deficiency.

The main typical pathways were identified between subclinical VE deficient and control cows by KEGG. For KEGG signaling pathway analysis, these subclinical VE deficiency-related proteins are mainly involved in the MAPK signaling pathway, and these subclinical VE deficiency downregulated differential-related proteins are mainly involved in pantothenate and CoA biosynthesis, PPAR signaling pathway, GPI-anchor biosynthesis. Mitogen-activated protein kinases (MAPKs) are a kind of protein kinases that regulate cell proliferation, differentiation, apoptosis, and migration (44). Mitogen-activated protein kinase activation
interacts with protein lipase to change cell behavior rapidly in response to environmental changes (45). The upregulated protein monocyte differentiation antigen CD14 (CD14) and downregulated protein interleukin 1 receptor accessory protein (IL-1RAP) were related to the MAPK signaling pathway. CD14 is a pattern recognition receptor (PRR) of the innate immune system. After recognizing pathogen associated molecular pattern (PAMP), CD14 transmits signals to cells to activate transcription factors and initiate inflammatory reaction (46). Interleukin 1 receptor accessory protein is a kind of auxiliary protein IL-1 signaling pathways, involved in the IL-1 functional receptors (IL-1R I) that both belong to the immunoglobulin superfamily member (47). Interleukin 1 receptor accessory protein increases the supply of cysteine through uptake and biogeneration and controls cysteine metabolism to participate in regulating oxidative stress (48). The downregulation of plasma IL1RAP in dairy cows with subclinical VE deficiency may be due to its involvement in the regulation of cysteine metabolism. Cysteine metabolism is a key substrate and determinant of antioxidant glutathione (GSH) synthesis (48). Plasma CD14 protein expression was up-regulated and IL-1RAP protein expression was down-regulated, suggesting that stress and inflammation were more serious in cows with subclinical VE deficiency.

Glycosylphosphatidylinositol-anchored modification is one of the most common post-translational modifications of eukaryotic cell membrane proteins (49, 50). Glycosylphosphatidylinositol-anchored biosynthesis pathway related protein phosphatidylinositol glycosyl specific phospholipase D (GPLD) was downregulated in post-partum VE-deficient dairy cows. Glycosylated phosphatidylinositol specific phospholipase D (GPI-PLD) in plasma can specifically act on the GPI-anchored substrate in the presence of detergents, thus releasing anchored proteins and phospholipid acids (51). Liver is an important source of plasma GPI-PLD in both human
and bovine (52, 53). The lysosomes of hepatocytes are rich in GPI-PLD, which plays an important role in the degradation of GPI and GPI-anchored proteins in hepatocytes. It is speculated that GPI-PLD in hepatocytes may enter plasma with HDL secreted by hepatocytes (54). Therefore, liver diseases may affect the activity of GPI-PLD in plasma. Downregulation of plasma GPLD1 in dairy cows with subclinical VE deficiency indicated that oxidative stress aggravates abnormal liver metabolism and
abnormal degradation of GPI and GPI-anchored protein of dairy cows with subclinical VE deficiency.

Pantothenic acid (PA) and its salts, as a component of coenzyme A (CoA) or acyl carrier protein (ACP), play an important role in many metabolic reactions (55). Coenzyme A-bound PA is involved in the energy release of carbohydrates, fatty acids, and amino acids. The PA binding to ACP is related to the synthesis of fatty acids (56). In the post-partum subclinical VE deficiency group, PA and CoA biosynthesis pathway-related protein pantothenyl thioglycolaminase (VNN1) were downregulated. VNN1 is a kind of oxidative stress sensor rich in the liver, which is a GPI-anchored pantothenase. It is involved in the regulation of multiple metabolic pathways and is highly expressed in the liver, intestine, and kidney (57, 58). Its pantothenase activity hydrolyzes PA into PA (vitamin B5) and cysteamine (59). Some studies have shown that VNN1 deficiency can increase liver GSH levels (60, 61). In this study, VNN1 was downregulated in subclinical VE-deficient dairy cows after middle production, which may be due to the increase of liver GSH level to resist oxidative stress.

Subclinical VE deficiency in cows in the early post-partum period can aggravate oxidative stress and inflammation and aggravate abnormal lipid metabolism in cows (11, 62, 63). Vitamin E is a major protective agent for circulation and intracellular lipid peroxidation, which can reduce the level of cellular oxidative stress and improve the functional environment of intracellular signaling pathways. It has anti-inflammatory and antioxidative effects (64). The five candidate proteins (APOC3, APOC4, SAA4, PHLD, and VNN1) were identified by interaction network analysis and literature review. The DEPs were further verified by enzyme-linked immunosorbent assay and Western blot. APOC3, VNN1, and SAA4 all had significantly lower expression levels than the healthy control group. APOC3 plays a role in PPARα metabolism by controlling lipolysis of PPARα ligands (65). VNN1 is an important target gene of PPARα, which participates in regulating its activity (66–68). VNN1 is involved in oxidative stress and inflammation by regulating the synthesis of cysteamine and GSH (69, 70). Under physiological conditions, SAA4 accounts for more than 90% of the total SAA (29). However, its concentration did not increase in the inflammatory state, but showed a downward trend (30, 31). As a new molecule of concern, SAA4 may be one of the diagnostic markers of post-partum cow subclinical VE deficiency. More research is needed to explore the regulatory mechanisms of APOC3, VNN1, and SAA4 proteins against the dairy cow subclinical VE deficiency and how the three proteins interact.

CONCLUSIONS

In this study, proteomic TMT methods were used to reveal the subclinical deficiency of cow VE in the early post-partum period and changes in plasma protein abundance in healthy control. Subclinical VE-deficient cows aggravate oxidative stress, abnormal lipid metabolism, and immunosuppression. The top canonical pathways and biological functions identified by KEGG and GO indicate this. Based on the different abundance of proteins in these pathways, fat mobilization, ROS production, and inflammatory immune response of subclinical VE-deficient dairy cows increased, which would cause the body to be susceptible to infection. These changes of oxidative stress and inflammation-related proteins may be related to early lactation diseases and slow recovery of reproductive performance. These findings contribute to further research to better understand the molecular mechanism of protein changes that may promote inflammation and oxidative stress.

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the IPROX repository, ProteomeXchange ID: PXD026856. The link is https://www.iproxn.cn/page/PSV023.html?url=1624347711767BLKj, view password is jWOm.

ETHICS STATEMENT

The animal study was reviewed and approved by Heilongjiang Bayi Agricultural University Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

WQ, SF, and CX conceived the study, interpreted the data, and wrote the manuscript. WQ, HY, CZ, XS, HZ, SF, and CX carried out experiments and data analysis. All authors approved the final version.

FUNDING

This work was supported by the Natural Science Foundation of Heilongjiang Province (ZD2021C006), National Natural Science Foundation of China (Beijing, China; Grant Number 31873028), and Daqing Guiding Science and Technology Plan Project (zd-2020–49). Heilongjiang Bayi Agricultural University’s scientific research start plan for introducing talents(XYB202101); Heilongjiang Natural Science Foundation joint guide project (LH2020C085) and supported by the special Fund for the construction of modern agricultural (dairy cow) industrial technology system (CARS-36).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2021.723898/full#supplementary-material.
ketosis, left displacement of the abomasum, milk fever and retained placenta. J Vet Med Sci. (2001) 63:227-30. doi: 10.1292/jvms.63.227

42. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. (2001) 20: 499-508. doi: 10.1016/s0945-053x(01)00172-x

43. Fonožūs I, Turk R, Duričić D, Vince S, Pleadin J, Flegar-Mestrić Z, et al. Influence of body condition on serum metabolic indicators of lipid mobilization and oxidative stress in dairy cows during the transition period. Reprod Domest Anim. (2015) 50:910-7. doi: 10.1111/rda.12608

44. Seternes OM, Kidger AM, Keyse SM. Dual-specificity MAP kinas e. Vitamins in Foods: Analysis. Bioavailability, and Stability. (2004) 4:372-7. doi: 10.1016/j.coph.2004.03.009

45. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. (2004) 4:372-7. doi: 10.1016/j.coph.2004.03.009

46. Joffre O, Nolte MA, Spérier R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev. (2010) 227:234-47. doi: 10.1111/j.1600-065X.2008.00718.x

47. Boraschi D, Italiani P, Weil S, Martin MU. The family of the interleukin-1 receptors. Immunol. (2018) 281:197-232. doi: 10.1111/imr.12606

48. Zhang H-F, El-Naggar AM, Cheng H, Prudova A, Delaïdéli A, He J-Z, et al. IL1RAP augments cytokine metabolism and drives oxidative stress adaptation and lung metastasis in Ewing sarcoma. Cancer Res. (2020) 80:6080-6080. doi: 10.1158/1073-0335.IA-1654

49. Orlean P, Menon AK. Thematic review series: lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycoprophospholipids. J Lipid Res. (2007) 48:993–1011. doi: 10.1194/jlr.R700002-JLR200

50. Menon AK. Glycosylphosphatidylinositol anchors. In: Lennarz WJ, Lane MD, editors. Encyclopedia of Biological Chemistry. London: Academic Press. (2013): 476–8. doi: 10.1016/B978-0-12-378630-2.00211-5

51. Jones DR, Avila MA, Sanz C, Varela-Nieto I. Glycosyl- phosphatidylinositol-phospholipase D: a possible candidate for the generation of second messengers. Biochem Biophys Res Commun. (1997) 233:432-7. doi: 10.1016/S0006-291X(97)6475

52. Rhode H, Lopatta E, Schulze M, Pascual C, Schulze HP, Schubert K, et al. Glycosylphosphatidylinositol-specific phospholipase D in blood serum: is the liver the only source of the enzyme?. Clin Chim Acta. (1999) 281:127–45. doi: 10.1016/S0009-8981(98)00218-6

53. GPl, PDI. In: Schwab M, editors. Encyclopedia of Cancer. Frontiers in Veterinary Science | www.frontiersin.org 13 December 2021 | Volume 8 | Article 723898

54. Menon AK. Phosphatidylinositol-glycan-specific phospholipase type D: a possible candidate for the generation of second messengers. Biochem Biophys Res Commun. (1999) 268:747–57. doi: 10.1011/j/bbrc.1999.6475

55. Ragaller V, Lebhien P, Sudheer KH, Häther L, Flachowsky G. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of vanin-1 deficient mice. FEBS Lett. (2000) 483:149–54. doi: 10.1016/S0014-5793(00)02110-4

56. Barro D, Dupré S, Pitari G. Is pantetheinase the actual identity of mouse and human vanin-1 proteins? FEBS Letters. (1999) 461:149–52. doi: 10.1016/S0014-5793(99)01439-8

57. Hayes JD, McElhaney LI. Glutathione and glutathione-dependent enzymes represent a coordinately regulated defence against oxidative stress. Free Radic Res Commun. (1999) 31:273–300. doi: 10.1080/10715769900300851

58. Seternes OM, Kidger AM, Keyse SM. Dual-specificity MAP kinas e. Vitamins in Foods: Analysis. Bioavailability, and Stability. (2004) 4:372-7. doi: 10.1016/j.coph.2004.03.009

59. Maras B, Barra D, Dupré S, Pitari G. Is pantetheinase the actual identity of mouse and human vanin-1 proteins? FEBS Letters. (1999) 461:149–52. doi: 10.1016/S0014-5793(99)01439-8

60. Hayes JD, McElhaney LI. Glutathione and glutathione-dependent enzymes represent a coordinately regulated defence against oxidative stress. Free Radic Res Commun. (1999) 31:273–300. doi: 10.1080/10715769900300851

61. Berruyer C, Martin FM, Castellano R, Macone A, Malgere F, Garrido-Urbaní S, et al. Vanin-1://-- mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol Cell Biol. (2004) 24:7214–24. doi: 10.1128/MCB.24.16.7214-7224.2004

62. Baldi A. Vitamin E in dairy cows. Livestock Product Sci. (2005) 98:117–22. doi: 10.1016/j.livprodsci.2005.10.004

63. Spears JW, Weiss WP. Role of antioxidants and trace elements in health and immunity of transition dairy cow. Vet J. (2008) 176:70–6. doi: 10.1016/j.tvjl.2007.12.015

64. Joy M, Chakraborty K. Antioxidative and anti-inflammatory pyridoids and isocrohmene analogues from Corbiculid bivalve clam, Villorita cyprinoides. Food Chem. (2018) 251:125–34. doi: 10.1016/j.foodchem.2018.01.059

65. Ziouzenkova O, Plutzky J. Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? Curr Opin Clin Nutr Metab Care. (2004) 7:369. doi: 10.1016/j.mco.2000.134358.46159.61

66. Moffit JS, Koza-Taylor PH, Holland RD, Thibodeau MS, Beger RD, Lawton MP, et al. Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate. Toxicol Appl Pharmacol. (2007) 222:169–79. doi: 10.1016/j.taap.2007.04.008

67. Rommelmae e, Mellet V, Gensollen T, Bourges C, Eckhoute J, Hennuyer N, et al. PPARalpha regulates the production of serum Vanin-1 by liver. FEBS Lett. (2013) 587:3742–8. doi: 10.1016/j.fleslet.2013.09.046

68. Rakhsh M, Knoch B, Müller M, Kersten E. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. (2010) 2010:393–416. doi: 10.1155/2010/612089

69. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. (2002) 23:599–622. doi: 10.1210/er.2001-0039

70. Tan KS, Lee KO, Low KC, Gamage AM, Liu Y, Tan YGG, et al. Glutathione deficiency in type 2 diabetes impairs cytokine responses and control of intracellular bacteria. J Clin Invest. (2012) 122:2289. doi: 10.1172/JCI75817

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Qian, Yu, Zhang, Zhang, Fu and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.